We did not observe shared genetic risk factors between de novo and cisplatin-induced tinnitus. Our results suggest that genetic risk factors are mainly distinct based on etiology of tinnitus and future efforts to study, prevent or treat tinnitus are expected to benefit from strategies that allow for distinction of cases based on the primary environmental risk factor.

1 day ago

Journal

PD-L1 (Programmed death ligand 1) • FOXM1 (Forkhead Box M1)

cisplatin

A novel machine learning model integrating clinical and molecular data to predict response to second line treatment in recurrent IDHwtglioblastoma (AIOM 2024)

Background : Nitrosoureas (lomustine/fotemustine) and antiangiogenic drugs (bevacizumab or regorafenib) are second-line treatment options for patients with recurrent IDHwt-glioblastoma (rGBM). The multi-classification ML model developed in this study was able to identify clinical and molecular signatures of recurrent glioblastoma patients responding to specific second-line treatment with bevacizumab or regorafenib or nitrosoureas.

1 day ago

Clinical • Machine learning

EGFR (Epidermal growth factor receptor) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • MTAP (Methylthioadenosine Phosphorylase) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)

TP53 mutation • EGFR mutation • PTEN mutation • IDH wild-type • MTAP mutation

FoundationOne® CDx

Avastin (bevacizumab) • Stivarga (regorafenib) • lomustine • Muphoran (fotemustine)

PTEN alteration as a predictor of second-line efficacy in patients with recurrent IDHwt-glioblastoma (rGBM) (AIOM 2024)

Nitrosoureas (NS) such as lomustine and fotemustine and antiangiogenic drugs such as regorafenib(Reg) and bevacizumab (Bev) are all treatment options for rGBM. We concluded that pathogenic PTEN alteration may be a predictor of poor efficacy of regorafenib and lomustine in rGBM patients. However, a prospective study with a larger population is needed to better define the role of pTEN in these patient populations.

1 day ago

Clinical

PTEN (Phosphatase and tensin homolog) • MGMT (6-O-methylguanine-DNA methyltransferase)

PTEN mutation • IDH wild-type

FoundationOne® CDx

Avastin (bevacizumab) • Stivarga (regorafenib) • lomustine • Muphoran (fotemustine)

PROGNOSTIC SIGNIFICANCE OF CIRCULATING TUMOR CELLS NUMBER AND PHENOTYPE IN A COHORT OF EARLY STAGE NON-SMALL-CELL LUNG CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY (AIOM 2024)

Preclinical evidence from NSCLC models showed that cell damage caused by cisplatin activates the SDF-1/CXCR4 axis, leading to the recruitment of metastasis initiating cells (MICs), a prometastatic cell subset co-expressing the stemness marker CD133 and CXCR4 (SDF-1 receptor)... CTCs may represent a novel biomarker for monitoring chemotherapy efficacy in NSCLC. An increased number of CTCs baseline and after pb-NACT, as well as after surgery represent a negative prognostic factor for survival. A higher number of CXCR4+CTCs at baseline correlated with inferior response outcomes after pb-NACT, prompting consideration for treatment intensification in pts with higher baseline levels of this CTC subtype.

1 day ago

Clinical • Circulating tumor cells • Tumor cell

CXCL12 (C-X-C Motif Chemokine Ligand 12)

CD133 expression

Parsortix Liquid Biopsy

cisplatin

Homologous recombination (HR) and DNA damage repair (DDR) somatic alterations in metastatic colorectal cancer (mCRC): results from the comprehensive genomic profiling (CGP) trial FPG500 (AIOM 2024)

Background : Treatment (tx) of MSS/MMRp mCRC relies mainly on oxaliplatin (oxa)- or irinotecan-based doublet chemotherapy regimens, with no biomarker reported so far, allowing the selection of one tx over the other. HR-DDRa is associated with MSI-H or TMB-H. Pts with MSS HR-DDRa tumors benefit from oxa-based first line treatment. Longer FU, allowing mature OS data, and wider cohorts are warranted.

1 day ago

Tumor mutational burden • BRCA Biomarker • MSi-H Biomarker • Metastases

TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • BAP1 (BRCA1 Associated Protein 1) • PALB2 (Partner and localizer of BRCA2) • ATRX (ATRX Chromatin Remodeler) • CHEK2 (Checkpoint kinase 2) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD50 (RAD50 Double Strand Break Repair Protein) • CHEK1 (Checkpoint kinase 1) • BARD1 (BRCA1 Associated RING Domain 1) • MRE11A (MRE11 homolog, double strand break repair nuclease) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • FANCL (FA Complementation Group L) • FANCD2 (FA Complementation Group D2) • FANCE (FA Complementation Group E) • FANCC (FA Complementation Group C)

TMB-H • MSI-H/dMMR

TruSight Oncology 500 Assay

oxaliplatin • irinotecan

First results from the Italian cholangiocarcinoma dataset (ANITA): extended molecular profiling (EMP), access to targeted treatment (TT) and clinical characterization of FGFR2- rearranged and IDH1-mutated advanced biliary tract cancers (BTC) (AIOM 2024)

Among pts with EMP available, 64.2% had intrahepatic cholangiocarcinoma and 69.8% received CT1 (36.1% cisplatinum-gemcitabine). Despite a broader availability of EMP in advanced BTC in recent years, access to TT remains suboptimal even in referral Institutions. Our results demonstrate TT administration as a pivotal positive prognostic factor in a real-world setting, whilst FGFR2 or IDH1 alterations did not act as prognostic determinants per-se. Therefore, strategies aiming at improving the rate of patients receiving TT are warranted.

1 day ago

Clinical • Metastases

FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)

IDH1 mutation • FGFR2 mutation • FGFR2 fusion • IDH1 R132

FoundationOne® CDx

cisplatin • gemcitabine

The Inflammatory Characteristics of Symptomatic Glioma Associated With Poor Prognosis and Chemoresistance via Tumor Necrosis Factor Signaling Pathway. (PubMed, Brain Tumor Res Treat)

The findings suggest that symptomatic glioma enhances inflammatory responses linked to poor prognosis and chemoresistance. This supports the hypothesis that immediate treatment of incidental glioma may improve patient outcomes over a wait-and-see approach.

1 day ago

Journal

TNFA (Tumor Necrosis Factor-Alpha)

temozolomide

FOXD1 activates KIFC1 to modulate aerobic glycolysis and reinforce cisplatin resistance of breast cancer. (PubMed, Reprod Biol)

FOXD1 activates the glycolysis pathway by upregulating KIFC1, thereby facilitating BC cells' DDP resistance. Therefore, the FOXD1/KIFC1 axis linked the glycolysis pathway to DDP resistance and may be a promising new target for reinforcing DDP resistance in BC.

1 day ago

Journal

FOXD1 (Forkhead Box D1) • KIFC1 (Kinesin Family Member C1)

FOXD1 expression • KIFC1 expression

cisplatin

Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization. (PubMed, Hum Vaccin Immunother)

Opt TCR-T cells exhibited higher TCR transduction efficiency, higher TCR expression levels, higher avidity, and greater cytotoxicity than did Ori TCR-T cells. These results suggest that HLA-A*02:01/CLSPN1254-1262 specific Opt TCR-T cells are promising candidates for CDDP combination therapy.

1 day ago

Journal • IO biomarker

HLA-A (Major Histocompatibility Complex, Class I, A)

HLA-A*02

cisplatin

Advances in research on the carcinogenic mechanisms and therapeutic potential of YAP1 in bladder cancer (Review). (PubMed, Oncol Rep)

Several studies have demonstrated that YAP1 is overexpressed in bladder cancer and is involved in adverse outcomes such as bladder cancer occurrence, progression, resistance to cisplatin and the recurrence of tumours...In addition, this study further explored the potential of YAP1 in the diagnosis and treatment of bladder cancer. This study aimed to explore the potential mechanism of YAP1 in the treatment of bladder cancer.

1 day ago

Review • Journal

YAP1 (Yes associated protein 1)

YAP1 overexpression

cisplatin

Predictive Value of Neutrophil Extracellular Traps in Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer. (PubMed, Mol Carcinog)

Cisplatin-based chemotherapy is the recommended therapy for muscle-invasive bladder cancer (MIBC)...Patients with high levels of NETs predicted poor response to neoadjuvant chemotherapy. This study was the first to reveal the correlation between the level of NETs in MIBC and the efficacy of chemotherapy, which may provide a theoretical basis regarding NETs inhibitors.

1 day ago

Journal • BRCA Biomarker

BRCA2 (Breast cancer 2, early onset) • ERCC2 (Excision repair cross-complementation group 2)

BRCA2 mutation • ERCC2 mutation

cisplatin

Serum lactate dehydrogenase as a prognostic marker for treatment response in IDH wild-type glioblastoma patients undergoing stupp protocol. (PubMed, J Neurooncol)

Elevated LDH levels before starting the Stupp protocol are clinically significant as they predict poorer overall survival and progression-free survival in glioblastoma patients and worse RR. Incorporating LDH measurements into treatment planning can help identify patients at higher risk of poor outcomes, allowing for more tailored and potentially aggressive treatment strategies to improve management and therapeutic responses in glioblastoma.

1 day ago

Journal

MGMT (6-O-methylguanine-DNA methyltransferase)

LDH elevation • MGMT promoter methylation • LDH-L • IDH wild-type

temozolomide

LINC00470 promotes malignant progression of testicular germ cell tumors. (PubMed, Mol Biol Rep)

LINC00470 may play a significant role in the etiology and metastasis of TGCT through EMT and AKT-mediated signaling pathways.

1 day ago

Journal

TGFB1 (Transforming Growth Factor Beta 1) • LINC00470 (Long Intergenic Non-Protein Coding RNA 470)

cisplatin

Hua-Zhuo-Jie-Du Decoction Combined with Cisplatin Inhibits the Development of Gastric Cancer Cells by Regulating Immune and Autophagy Signaling. (PubMed, Biol Pharm Bull)

However, TDP alleviated these effects. These results collectively indicated that the combination of TDP with DDP can inhibit the development of gastric cancer cells by mediating the immune and autophagy signaling pathways.

1 day ago

Journal

CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • MMP2 (Matrix metallopeptidase 2) • CASP3 (Caspase 3) • CD31 (Platelet and endothelial cell adhesion molecule 1) • IL17A (Interleukin 17A) • MMP9 (Matrix metallopeptidase 9) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1) • BECN1 (Beclin 1)

CD31 expression

cisplatin

GPR68 supports AML cells through the calcium/calcineurin pro-survival pathway and confers chemoresistance by mediating glucose metabolic symbiosis. (PubMed, Biochim Biophys Acta Mol Basis Dis)

As glucose metabolic symbiosis and the heterogeneous dependencies on aerobic glycolysis and cellular respiration tremendously impact chemosensitivity, the inhibition of GPR68 potentiated the tumoricidal effect of first-line chemotherapeutic agents, including BCL-2 inhibitors targeting OxPhos and cytarabine (AraC) targeting glycolysis...The overexpression of GPR68 drives a Ca2+/CaN pro-survival pathway and mediates glucose metabolic symbiosis in AML cells, suggesting the diagnostic and therapeutic potential of GPR68 in AML. (GPR68, G proton-coupled receptor 68; PLCβ, phospholipase C beta; CaN, Calcineurin; IDH, isocitrate dehydrogenase; HIF-1α, Hypoxia-inducible factor alpha subunit; GLUT1, Glucose transporter type 1; HK-1, Hexokinase 1).

2 days ago

Journal • IO biomarker

HIF1A (Hypoxia inducible factor 1, alpha subunit) • CAPN1 (Calpain 1) • SLC2A1 (Solute Carrier Family 2 Member 1)

cytarabine

Euphorbia helioscopia inhibits proliferation, invasion, and migration and promotes apoptosis of non-small cell lung cancer cells (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)

Euphorbia helioscopia can inhibit proliferation, invasion, and migration and induces apoptosis of NSCLC cells in vitro.

2 days ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CDH1 (Cadherin 1) • MMP2 (Matrix metallopeptidase 2) • BAX (BCL2-associated X protein) • VIM (Vimentin) • MMP9 (Matrix metallopeptidase 9)

BCL2 expression • CDH1 expression • BAX expression • VIM expression

cisplatin

Cisplatin promotes TNF-α autocrine to trigger RIP1/RIP3/MLKL-dependent necroptosis of human head and neck squamous cell carcinoma cells (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)

Cisplatin activates nuclear factor-κB signaling in HNSCCs to promote TNF-α autocrine and induce RIP1/RIP3/MLKL-dependent necroptosis, thus leading to inhibition of cell proliferation.

2 days ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • CDH1 (Cadherin 1) • VIM (Vimentin) • CASP8 (Caspase 8) • CDH2 (Cadherin 2) • RIPK1 (Receptor Interacting Serine/Threonine Kinase 1) • RELA (RELA Proto-Oncogene)

CDH1 expression • VIM expression

cisplatin

LncRNA MAGI2-AS3 enhances cisplatin sensitivity of non-small cell lung cancer cells by regulating the miR-1269a/PTEN/AKT pathway (PubMed, Nan Fang Yi Ke Da Xue Xue Bao)

MAGI2-AS3 enhances DDP sensitivity of NSCLC by targeted regulation of the miR-1269a/PTEN/AKT signaling axis.

2 days ago

Journal

MIR1269A (MicroRNA 1269a) • MAGI2-AS3 (MAGI2 Antisense RNA 3)

PTEN expression

cisplatin

Carnosol alleviates cisplatin-induced acute kidney injury by regulating apoptosis and pyroptosis. (PubMed, Cell Biol Int)

Finally, CA reduced the level of cleaved caspase-1, but those of GSDMD and NLRP3 protein were not significantly different after treatment with the NLRP3 inhibitor MCC950 and were elevated by the NLRP3 activator nigericin. In conclusion, this study revealed that CA protects against CP-induced AKI by decreasing apoptosis and NF-κB/NLRP3/GSDMD-mediated pyroptosis, which provides new insight into the prevention of AKI.

2 days ago

Journal

TNFA (Tumor Necrosis Factor-Alpha) • HMGB1 (High Mobility Group Box 1) • IL18 (Interleukin 18) • KIM1 (Kidney injury molecule 1) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3) • RELA (RELA Proto-Oncogene)

cisplatin

Succinate dehydrogenase deficiency-driven succinate accumulation induces drug resistance in acute myeloid leukemia via ubiquitin-cullin regulation. (PubMed, Nat Commun)

Notably, decreasing succinate by fludarabine can restore the sensitivity of anti-cancer drugs in SDH-deficient AML. Together, we uncover the function of succinate in driving drug resistance by regulating p-UBC12/cullin activity, and indicate reshaping succinate metabolism as a promising treatment for SDH-deficient AML.

2 days ago

Journal

UBE2M (Ubiquitin Conjugating Enzyme E2 M)

fludarabine IV

Long non-coding RNA AC105118.1 affects glycolysis to facilitate oxaliplatin resistance in colorectal cancer cells by modulating the miR-378a-3p/KIF26B axis. (PubMed, Int J Biochem Cell Biol)

AC105118.1 facilitates glycolysis and increases CRC cells' resistance to oxaliplatin by targeting the miR-378a-3p/KIF26B axis. The present work shed new insights into the function and mechanism of AC105118.1 in molecular function and suggested that the AC105118.1/miR-378a-3p/KIF26B axis is a promising target for intervening CRC oxaliplatin resistance.

2 days ago

Journal

LDHA (Lactate dehydrogenase A) • MIR378A (MicroRNA 378a) • SLC2A1 (Solute Carrier Family 2 Member 1) • KIF26B (Kinesin Family Member 26B)

oxaliplatin

IL-21/IL-21R signaling renders acute myeloid leukemia stem cells more susceptible to cytarabine treatment and CAR T cell therapy. (PubMed, Cell Rep Med)

Low-dose IL-21 treatment prolongs the survival of AML mice in syngeneic and xenograft experiments. Therefore, promoting IL-21/IL-21R signaling on LSCs may be an approach to reduce stemness and increase differentiation in AML.

2 days ago

Journal • CAR T-Cell Therapy

CD70 (CD70 Molecule) • CD4 (CD4 Molecule) • IL21 (Interleukin 21)

cytarabine

LncRNA-mediated regulation of cisplatin response in breast cancer. (PubMed, Pathol Res Pract)

These lncRNAs include SNHG15, HULC, HCP5, MT1JP, LncMat2B, DLX6-ASL, Linc00665, CARMN, and Lnc-EinRP44-3:6. These lncRNAs have been shown to target microRNAs and mRNAs and modulate the expression of genes involved in cisplatin resistance, which is important in treating breast cancer.

2 days ago

Review • Journal

SNHG5 (Small Nucleolar RNA Host Gene 5) • HULC (Hepatocellular Carcinoma Up-Regulated Long Non-Coding RNA) • LINC00665 (Long Intergenic Non-Protein Coding RNA 665) • SNHG15 (Small Nucleolar RNA Host Gene 15)

cisplatin

Reconstructing the regulatory programs underlying the phenotypic plasticity of neural cancers. (PubMed, Nat Commun)

Applying this method to adult and childhood brain cancers, we identify critical regulators and suggest interventions that could improve temozolomide treatment in glioblastoma...Finally, scregclust's flexibility is demonstrated across 15 tumor types, uncovering both pan-cancer and specific regulators. The algorithm is provided as an easy-to-use R package that facilitates the exploration of regulatory programs underlying cell plasticity.

2 days ago

Journal

IRF8 (Interferon Regulatory Factor 8) • SPI1 (Spi-1 Proto-Oncogene)

temozolomide

Hyperthermia reduces cancer cell invasion and combats chemoresistance and immune evasion in human bladder cancer. (PubMed, Int J Oncol)

It was found that HT inhibited the proliferation of BC cells by downregulating the phosphorylation of protein kinase B. Moreover, HT effectively enhanced the sensitivity of BC cells to the chemotherapy drug cisplatin (DDP) and reduced the chemoresistance of DDP‑resistant cells by downregulating the expression of cadherin‑11...In summary, the antineoplastic effects of HT were mediated through three main mechanisms: Enhancement of the chemosensitivity of BC cells and mitigation of DDP‑induced chemoresistance, suppression of the invasive potential of BC cells and reinforcement of the anticancer response of NK cells. Thus, HT appears to be a promising adjunctive therapy for human BC.

2 days ago

Journal

CDH11 (Cadherin 11)

cisplatin

Osteosarcoma stem cells resist chemotherapy by maintaining mitochondrial dynamic stability via DRP1. (PubMed, Int J Mol Med)

Furthermore, treatment of OSCs with cisplatin (CIS) or doxorubicin (DOX) resulted in preserved mitochondrial morphological stability, which was not observed in non‑OSCs. These findings unveil a novel mechanism underlying chemoresistance in osteosarcoma and suggest that targeting DRP1 could be a promising therapeutic strategy to overcome chemoresistance in OSCs. This provided valuable insights for enhancing treatment outcomes among patients with osteosarcoma.

2 days ago

Journal

DNM3 (Dynamin 3)

cisplatin • doxorubicin hydrochloride

N6-methyladenosine regulators in hepatocellular carcinoma: investigating the precise definition and clinical applications of biomarkers. (PubMed, Biol Direct)

Our findings suggest that the mutual validation of big data analysis and functional experiments may facilitate the precise identification and definition of biomarkers, and our m6A risk models may have the potential to guide personalized chemotherapy, targeted treatment, and immunotherapy decisions in HCC.

2 days ago

Journal • PD(L)-1 Biomarker • IO biomarker

CTLA4 (Cytotoxic T-Lymphocyte Associated Protein 4)

gemcitabine • sorafenib

Curcumol Enhances the Sensitivity of Gastric Cancer to Cisplatin Resistance by Inducing Ferroptosis Through the P62/KEAP1/NRF2 Pathway. (PubMed, Integr Cancer Ther)

This study first revealed that CUR enhanced the sensitivity of cisplatin-resistant GC cells to CDDP by inducing ferroptosis. The combination of CUR and CDDP induces ferroptosis in cisplatin-resistant GC through the P62/KEAP1/NRF2 pathway.

2 days ago

Journal

GPX4 (Glutathione Peroxidase 4)

cisplatin

Distinctive grade based on Ki67 index and immune microenvironment of metastatic pancreatic neuroendocrine tumors responding to capecitabine plus temozolomide. (PubMed, BMC Cancer)

Grade based on Ki67 index and immune environment change in PanNET patients responding well to CapTem. Patients with downgraded had longer mPFS compared to those with upgraded. It is necessary to reassess the Ki67 index after CapTem treatment, even in patients responding well to CapTem.

2 days ago

Retrospective data • Journal • Metastases

IL2RA (Interleukin 2 receptor, alpha) • CD163 (CD163 Molecule) • CD33 (CD33 Molecule) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule) • ITGAM (Integrin, alpha M) • MRC1 (Mannose Receptor C-Type 1) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule) • ISG20 (Interferon Stimulated Exonuclease Gene 20)

temozolomide • capecitabine

Bioinformatic and clinical experimental assay uncovers resistance and susceptibility mechanisms of human glioblastomas to temozolomide and identifies new combined and individual survival biomarkers outperforming MGMT promoter methylation. (PubMed, Ther Adv Med Oncol)

In this study, a comprehensive analysis of the expression of 361 DNA repair genes and activation levels of 38 DNA repair pathways revealed 13 potential survival biomarkers with increased prognostic potential compared to MGMT methylation. We algorithmically reconstructed the TMZ sensitivity pathway with strong predictive capacity in GBM.

2 days ago

Journal

MGMT (6-O-methylguanine-DNA methyltransferase)

MGMT promoter methylation

temozolomide

Identification of basement membrane-related prognostic model associated with the immune microenvironment and synthetic therapy response in pancreatic cancer: integrated bioinformatics analysis and clinical validation. (PubMed, J Cancer)

PCs with a low BM-related score had a better outcome and were more likely to benefit from oxaliplatin, irinotecan, and KRAS(G12C) inhibitor-12, and immunotherapy. Molecular docking indicated that epigallocatechin gallate had a strong binding activity with DSG3, MET, and PLAU and may be used as a potential therapeutic agent for PC. In conclusion, this study developed a BM-related model associated with PC prognosis, immune infiltration, and treatment, which provided new insights into PC stratification and drug intervention.

3 days ago

Journal

KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • PLAU (Plasminogen Activator)

oxaliplatin • irinotecan

Huaier promotes sensitivity of colorectal cancer to oxaliplatin by inhibiting METTL3 to regulate the Wnt/β‑catenin signaling pathway. (PubMed, Oncol Rep)

Silencing METTL3 promoted apoptosis of CRC cells and increased their sensitivity to OXA by inhibiting the Wnt/β‑catenin signaling pathway. Huaier downregulated the expression of METTL3, thereby promoting apoptosis of drug‑resistant CRC cells and increasing their sensitivity to OXA by inhibiting the Wnt/β‑catenin signaling pathway.

3 days ago

Journal

METTL3 (Methyltransferase Like 3)

oxaliplatin

MicroRNA-505-5p/-3p Regulates the Proliferation, Invasion, Apoptosis, and Temozolomide Resistance in Mesenchymal Glioma Stem Cells by Targeting AUF1. (PubMed, Mol Carcinog)

Co-inhibition of AUF1 expression with miR-505-5p/-3p knockdown ameliorated the observed cellular phenotypes caused by miR-505-5p/-3p knockdown in MES-GSCs. These results suggest that miR-505-5p/-3p exerts MES-GSC-specific roles in regulating proliferation, differentiation, invasion, apoptosis, and temozolomide resistance by repressing AUF1 expression.

3 days ago

Journal

HNRNPD (Heterogeneous Nuclear Ribonucleoprotein D)

temozolomide

Safety Evaluations of Rapamycin Perfluorocarbon Nanoparticles in Ovarian Tumor-Bearing Mice. (PubMed, Nanomaterials (Basel))

The pharmacokinetics and biodistribution results revealed a significant enhancement in the delivery of rapamycin to tumors by rapamycin PFC nanoparticles, which, in turn, led to a significant reduction in ovarian tumor growth. Therefore, rapamycin PFC nanoparticles have the potential to be clinically beneficial in cisplatin-treated ovarian cancer patients.

3 days ago

Preclinical • Journal

TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)

cisplatin

Evaluation of Vincamine Loaded with Silver Nanoparticles as a New Potential Therapeutic Agent Against Ehrlich's Solid Carcinoma in Mice. (PubMed, Cells)

After tumor transplantation, the mice were divided into five groups: ESC, ESC+Cisplatin (CPN; 5 mg/kg), ESC+VCN (40 mg/kg), ESC+AgNPs (6 mg/kg), and ESC+VCN-AgNPs (20 mg/kg)...VCN-AgNPs possess cytotoxic and genotoxic effects against ESC because of their pro-oxidant, pro-apoptotic, pro-inflammatory, and antiangiogenic effects. Additionally, the combination of VCN-AgNPs was more effective and safer than chemically synthesized AgNPs, as indicated by an increase in the lifespan of animals and the total tumor inhibition index.

3 days ago

Preclinical • Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • TNFA (Tumor Necrosis Factor-Alpha) • CASP3 (Caspase 3) • IL1B (Interleukin 1, beta)

cisplatin

Glioma-Astrocyte connexin43 confers temozolomide resistance through activation of the E2F1/ERCC1 axis. (PubMed, Neuro Oncol)

Our study reveals a novel regulatory mechanism in which the Cx43/miR-205-5p/E2F1/ERCC1 axis contributes to TMZ resistance in glioma. These findings further highlight the potential of targeting Cx43 as a therapeutic strategy in glioma.

3 days ago

Journal

ERCC1 (Excision repair cross-complementation group 1) • GJA1 (Gap Junction Protein Alpha 1) • E2F1 (E2F transcription factor 1) • GFAP (Glial Fibrillary Acidic Protein) • MIR205 (MicroRNA 205)

GJA1 expression

temozolomide

TGF-β Signaling Loop in Pancreatic Ductal Adenocarcinoma Activates Fibroblasts and Increases Tumor Cell Aggressiveness. (PubMed, Cancers (Basel))

We conclude that TGF-β is only one of the players that mediates the communication between PDAC cells and fibroblasts and controls the acquisition of aggressive phenotypes. Hence, these advanced in vitro models may be exploited to further investigate these events and to design innovative anti-PDAC therapies.

3 days ago

Journal • Tumor cell

TGFB1 (Transforming Growth Factor Beta 1)

gemcitabine

Capecitabine enhances sensitivity to oxaliplatin in advanced gastric cancer and the effects on patients' FOXP1 and GGT levels. (PubMed, Heliyon)

Gastric cancer patients with age <60 years, TNM stage of Ⅰ ∼ Ⅱ, lymph node metastasis N0 ∼ N1, high expression of FOXP1, GGT <387.2, and combined with drug chemotherapy had higher survival rate. Capecitabine effectively enhanced the sensitivity of intermediate and advanced gastric cancer to oxaliplatin, improved the therapeutic effect, reduced the proportion of patients with low FOXP1 expression rate and serum GGT level, decreased the recurrence rate and ameliorated the prognosis of patients.

3 days ago

Journal • Metastases

FOXP1 (Forkhead Box P1)

capecitabine • oxaliplatin

Establishment and Clinical Significance of the Patient-Derived Xenograft Model of Colorectal Cancer. (PubMed, Cureus)

The CRC-PDX model established in this study can maintain the biological characteristics of primary tumors and can be used as a reference model for the individualized treatment of CRC patients. The degree of malignancy of the primary tumor is the primary factor affecting the tumorigenesis rate of the PDX model.

3 days ago

Preclinical • Journal

CEACAM5 (CEA Cell Adhesion Molecule 5)

5-fluorouracil • oxaliplatin

Patients with T4N0 and T1‑3N1 colon cancer and a high preoperative carcinoembryonic antigen level benefit from adjuvant chemotherapy with oxaliplatin for 6 months. (PubMed, Oncol Lett)

However, the prognosis of patients in the low-risk group with high CEA levels improved with a 6-month adjuvant treatment with oxaliplatin to a similar level to that of all patients with low CEA levels in the low-risk group. In conclusion, the present study suggested that the duration of adjuvant chemotherapy with oxaliplatin should not be shortened in patients with high preoperative CEA levels, even in the low-risk group.

3 days ago

Journal

CEACAM5 (CEA Cell Adhesion Molecule 5)

oxaliplatin

Isocitrate dehydrogenase 2 mutation promotes cytarabine resistance in acute myeloid leukemia by Warburg effect. (PubMed, Hematol Oncol)

To investigate cellular responses, the glycolytic inhibitor 2-deoxy-D-glucose (2-DG) was administered to the cells...The increase in glycolysis levels following IDH2 mutation may contribute to the reduced efficacy of Enasidenib in inhibiting the proliferation of IDH-mutant AML cells...BEZ235 significantly inhibits the expression of phosphorylated PI3K (p-PI3K), phosphorylated Akt (p-Akt), mTOR, glycolytic metabolism, and Ara-C resistance both in vitro and in vivo. Overexpression and mutation of IDH2 coordinate with the Warburg effect through the PI3K/Akt/mTOR pathway to promote Ara-C resistance in AML.

3 days ago

Journal

IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)

IDH2 mutation • IDH2 overexpression

cytarabine • dactolisib (RTB101) • Idhifa (enasidenib)

Pleural Bleomycin vs Mechanical Abrasion in Malignant Pleural Effusion (clinicaltrials.gov)

P=N/A, N=70, Not yet recruiting, Assiut University

3 days ago

New trial

bleomycin